MedTrace Logo

Cannabis for the Prophylactic Treatment of Migraine

NCT03972124 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2026-05-01

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of cannabis for the treatment of chronic migraine headaches. Study subjects will be randomized to one of three groups: lower dose CBD, higher dose CBD or placebo.

Conditions

  • Chronic Migraine

Interventions

DRUG

CBD 100 mg OD

CBD oil - purified to \<1% THC in soft-gel capsules

DRUG

CBD 200 mg OD

CBD oil - purified to \<1% THC in soft-gel capsules

DRUG

Placebo

Soft-gel capsules containing placebo

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03972124 on ClinicalTrials.gov